Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like How To Prevent Failure in Rare Disease Trials? Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials
Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like How To Prevent Failure in Rare Disease Trials? Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials
